Arni agent to inhibit expression of the beta e subunit of inhibin (inhbe), and use.

Abstract

This description relates to RNAi agents, for example, double-stranded RNAi agents such as siRNA, capable of inhibiting the gene expression of the inhibin beta-E subunit (INHBE). Pharmaceutical compositions containing INHBE RNAi agents and methods of their use are also described. The INHBE RNAi agents described herein can be conjugated with targeting ligands to facilitate delivery to cells, including hepatocytes. In vivo administration of INHBE RNAi agents results in the inhibition of INHBE gene expression. RNAi agents can be used in the treatment of diseases, disorders, or symptoms mediated in part by INHBE gene expression, such as obesity, diabetes, liver inflammation, dyslipidemia, or metabolic disease.